PURPOSE: The inability to predict clinical outcome of prostate cancer is a major impediment to effective treatment decisions and patient counseling. New markers of recurrence are needed to improve the accuracy of risk assessment and treatment of prostate cancer. Our previous studies identified a mismatch repair protein, PMS2, to be elevated in prostate cancer; here, we investigate the prognostic potential of this marker. We hypothesized that the elevation of PMS2 would correlate with disease outcome. EXPERIMENTAL DESIGN: Retrospective quantitative immunohistochemistry was done to measure PMS2 in high-grade cancers of 166 men treated by radical prostatectomy with a biochemical recurrence rate of 56%. Associations between PMS2 levels, pathologic variables, and biochemical recurrence over time were determined. RESULTS: The mean level of PMS2 protein was consistently higher in both cancer-associated benign epithelium and cancer cells of patients who recurred, compared with nonrecurrent patients. PMS2 was an independent predictor of time-to-recurrence in Cox multivariate analyses and significantly stratified patients based on outcome. PMS2 was able to improve the sensitivity of total percent Gleason 4/5 as a risk factor for recurrence in this cohort. CONCLUSIONS: PMS2 protein levels were shown to be a predictor of time-to-recurrence after surgery. This study is the first to document that the elevation of a mismatch repair protein negatively correlates with prognosis and has implications in patient diagnosis and molecular profiling.
PURPOSE: The inability to predict clinical outcome of prostate cancer is a major impediment to effective treatment decisions and patient counseling. New markers of recurrence are needed to improve the accuracy of risk assessment and treatment of prostate cancer. Our previous studies identified a mismatch repair protein, PMS2, to be elevated in prostate cancer; here, we investigate the prognostic potential of this marker. We hypothesized that the elevation of PMS2 would correlate with disease outcome. EXPERIMENTAL DESIGN: Retrospective quantitative immunohistochemistry was done to measure PMS2 in high-grade cancers of 166 men treated by radical prostatectomy with a biochemical recurrence rate of 56%. Associations between PMS2 levels, pathologic variables, and biochemical recurrence over time were determined. RESULTS: The mean level of PMS2 protein was consistently higher in both cancer-associated benign epithelium and cancer cells of patients who recurred, compared with nonrecurrent patients. PMS2 was an independent predictor of time-to-recurrence in Cox multivariate analyses and significantly stratified patients based on outcome. PMS2 was able to improve the sensitivity of total percent Gleason 4/5 as a risk factor for recurrence in this cohort. CONCLUSIONS:PMS2 protein levels were shown to be a predictor of time-to-recurrence after surgery. This study is the first to document that the elevation of a mismatch repair protein negatively correlates with prognosis and has implications in patient diagnosis and molecular profiling.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Donald C Malins; Naomi K Gilman; Virginia M Green; Thomas M Wheeler; Edward A Barker; Katie M Anderson Journal: Proc Natl Acad Sci U S A Date: 2005-12-16 Impact factor: 11.205
Authors: Yian Chen; Jiansong Wang; Mostafa M Fraig; Kelly Henderson; Nabil K Bissada; Dennis K Watson; Clifford W Schweinfest Journal: Int J Oncol Date: 2003-05 Impact factor: 5.650
Authors: William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick Journal: J Urol Date: 1994-05 Impact factor: 7.450
Authors: Atsuko Shibata; Maria Isabel Garcia; Iona Cheng; Thomas A Stamey; John E McNeal; James D Brooks; Stavonnie Henderson; Cheryl E Yemoto; Donna M Peehl Journal: Prostate Date: 2002-09-01 Impact factor: 4.104
Authors: Alan Pollack; Didier Cowen; Patricia Troncoso; Gunar K Zagars; Andrew C von Eschenbach; Marvin L Meistrich; Timothy McDonnell Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Tiziana Grassi; Angelo Calcagno; Stefania Marzinotto; Ambrogio P Londero; Maria Orsaria; Gioia N Canciani; Carlo Alberto Beltrami; Diego Marchesoni; Laura Mariuzzi Journal: Int J Clin Exp Pathol Date: 2015-02-01
Authors: Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Anju Bansal; Abha Soni; Punita Rao; L C Singh; Ashwani Kumar Mishra; N K Mohanty; Sunita Saxena Journal: Indian J Med Res Date: 2012-10 Impact factor: 2.375
Authors: Belinda Nghiem; Xiaotun Zhang; Hung-Ming Lam; Lawrence D True; Ilsa Coleman; Celestia S Higano; Peter S Nelson; Colin C Pritchard; Colm Morrissey Journal: Asian J Urol Date: 2016-09-12